We partner with countries and work at the global level to assess supply and demand for health products and build markets that address the five A’s: affordability, availability, assured quality, appropriate design, and awareness.
Research and development (R&D) into new medical products is the engine driving progress toward health for all. Regulatory approvals are essential to ensuring the safety and efficacy of these products—but regulatory processes differ from country to country across Africa, resulting in delays in introduction and scale-up.
Women want and need access to a variety of contraceptives to plan, space, and prevent pregnancies. PATH is expanding access and options with DMPA-SC (brand name Sayana® Press), an all-in-one contraceptive that puts women in charge of their reproductive health.
A national strategy focused on digital health, nutrition, and other high-impact interventions has dramatically improved health outcomes across India—but more work remains to be done.
A new resource sheds light on what’s needed to get ready for a new vaccine that, if approved, could help pregnant mothers protect their babies from a common cause of serious respiratory infections—respiratory syncytial virus.
At PATH, we connect local innovators and decision-makers with our global network of partners to develop responsive, human-centered solutions to health challenges.
Research in Uganda and elsewhere has shown that women are able to self-administer DMPA-SC safely and effectively, that they like doing so, and that self-injection helps support women to continue using injectable contraception.